FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033945237> ?p ?o ?g. }

• W3033945237 endingPage "688" @default.
• W3033945237 startingPage "688" @default.
• W3033945237 abstract "To compare the incidence, survival rate, and CT findings of acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) between patients with and without lung cancer.From June 2004 to July 2018, 89 consecutive patients diagnosed with IPF were included. Among them, 26 patients had IPF with lung cancer (IPF-LCA), and 63 patients had IPF alone. The clinical characteristics and CT findings associated with IPF, lung cancer, and AE were reviewed. Surgery and chemotherapy were performed for 6 and 23 cases of lung cancer, respectively, as the first- or second-line anticancer treatment. The overall survival, CT findings, disease-free period before AE, and duration from the onset of AE to death were compared.The incidence of AE was 61.5% in the IPF-LCA group and 58.7% in the IPF group (p = 0.806). The mean overall survival in the IPF-LCA and IPF groups were 16.8 and 83.0 months, respectively (p < 0.001). The mean durations from the start of the lung cancer treatment to the onset of AE were 16.0 and 4.6 months in cases of surgical treatment and chemotherapy, respectively. In comparison of death from AE, the survival rate was significantly lower in the IPF-LCA group than in the IPF group (p = 0.008). In the CT findings associated with AE, the IPF-LCA group tended to have a peribronchial (p < 0.001) or asymmetric distribution (p = 0.016).In patients with IPF who develop lung cancer, the rate of death from AE is higher than that in patients with IPF alone. They tend to have unusual CT patterns associated with AE, such as a peribronchial or asymmetric distribution.폐암이 동반된 특발성 폐섬유증 환자와 폐암 비동반 특발성 폐섬유증 환자에서 폐섬유증 급성 악화의 발병률, 생존율 및 전산화단층촬영 소견을 비교하고자 하였다.2004년 6월부터 2018년 7월까지, 특발성 폐섬유증으로 진단받은 89명의 환자를 대상으로 하였으며 26명의 폐암 동반 특별 폐섬유증 환자군과 63명의 폐암 비동반 특발 폐섬유증 환자군으로 구성되었다. 이들의 폐섬유증, 폐암, 급성 악화와 관련된 임상 검사 소견과 CT 소견을 검토하였다. 폐암 환자들은 1차 또는 2차 치료로 수술(n = 6), 항암치료(n = 23) 등을 받았다. 두 군 간에 생존율, 급성 악화의 CT 소견, 무병 기간과 급성 악화 발병 이후 사망까지의 시간을 비교하였다.급성 악화의 발병률은 폐암 동반군에서는 61.5%, 비동반군에서는 58.7%였다(p = 0.806). 폐암 동반군과 비동반군의 평균 생존 기간은 각각 16.8개월과 83.0개월이었다(p < 0.001). 치료 시작부터 급성 악화까지의 기간은 수술과 항암치료에서 각각 16.0개월과 4.6개월이었다. 급성 악화에 의한 사망을 비교하였을 때, 생존율은 폐암 동반군이 비동반군보다 유의하게 낮았다(p = 0.008). 급성 악화의 CT 소견은 폐암 동반군에서 기관지 주위 분포(p < 0.001)와 비대칭 분포(p = 0.016)를 보이는 경우가 많았다.폐암을 동반한 특발성 폐섬유증 환자에서, 급성 악화에 의한 사망률이 폐암 비동반 특발 폐섬유증 환자들보다 높았다. 또한, 기관지 주위 또는 비대칭 분포의 CT 소견을 보이는 경향이 있다." @default.
• W3033945237 created "2020-06-12" @default.
• W3033945237 creator A5000029465 @default.
• W3033945237 creator A5001489956 @default.
• W3033945237 creator A5006572100 @default.
• W3033945237 creator A5026187512 @default.
• W3033945237 creator A5026195368 @default.
• W3033945237 creator A5081370470 @default.
• W3033945237 date "2020-01-01" @default.
• W3033945237 modified "2023-09-27" @default.
• W3033945237 title "Acute Exacerbation of Idiopathic Pulmonary Fibrosis with Lung Cancer: A Comparative Analysis of the Incidence, Survival Rate, and CT Findings with the Patients without Lung Cancer" @default.
• W3033945237 cites W1966659784 @default.
• W3033945237 cites W1975073272 @default.
• W3033945237 cites W1979552392 @default.
• W3033945237 cites W1980656142 @default.
• W3033945237 cites W1986944821 @default.
• W3033945237 cites W2009183164 @default.
• W3033945237 cites W2014355881 @default.
• W3033945237 cites W2024492396 @default.
• W3033945237 cites W2031867428 @default.
• W3033945237 cites W2039472941 @default.
• W3033945237 cites W2076914293 @default.
• W3033945237 cites W2085336270 @default.
• W3033945237 cites W2090457466 @default.
• W3033945237 cites W2095516392 @default.
• W3033945237 cites W2100059970 @default.
• W3033945237 cites W2117098575 @default.
• W3033945237 cites W2122060090 @default.
• W3033945237 cites W2140793587 @default.
• W3033945237 cites W2157869208 @default.
• W3033945237 cites W2167189518 @default.
• W3033945237 cites W2167383172 @default.
• W3033945237 cites W2324276726 @default.
• W3033945237 cites W2440054067 @default.
• W3033945237 cites W2626588662 @default.
• W3033945237 cites W2770589251 @default.
• W3033945237 cites W1057029614 @default.
• W3033945237 doi "https://doi.org/10.3348/jksr.2020.81.3.688" @default.
• W3033945237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36238614" @default.
• W3033945237 hasPublicationYear "2020" @default.
• W3033945237 type Work @default.
• W3033945237 sameAs 3033945237 @default.
• W3033945237 citedByCount "0" @default.
• W3033945237 crossrefType "journal-article" @default.
• W3033945237 hasAuthorship W3033945237A5000029465 @default.
• W3033945237 hasAuthorship W3033945237A5001489956 @default.
• W3033945237 hasAuthorship W3033945237A5006572100 @default.
• W3033945237 hasAuthorship W3033945237A5026187512 @default.
• W3033945237 hasAuthorship W3033945237A5026195368 @default.
• W3033945237 hasAuthorship W3033945237A5081370470 @default.
• W3033945237 hasBestOaLocation W30339452371 @default.
• W3033945237 hasConcept C120665830 @default.
• W3033945237 hasConcept C121332964 @default.
• W3033945237 hasConcept C121608353 @default.
• W3033945237 hasConcept C126322002 @default.
• W3033945237 hasConcept C143998085 @default.
• W3033945237 hasConcept C2776256026 @default.
• W3033945237 hasConcept C2776283816 @default.
• W3033945237 hasConcept C2776694085 @default.
• W3033945237 hasConcept C2777014857 @default.
• W3033945237 hasConcept C2777543607 @default.
• W3033945237 hasConcept C2777714996 @default.
• W3033945237 hasConcept C2778341716 @default.
• W3033945237 hasConcept C2781244666 @default.
• W3033945237 hasConcept C61511704 @default.
• W3033945237 hasConcept C71924100 @default.
• W3033945237 hasConcept C90924648 @default.
• W3033945237 hasConceptScore W3033945237C120665830 @default.
• W3033945237 hasConceptScore W3033945237C121332964 @default.
• W3033945237 hasConceptScore W3033945237C121608353 @default.
• W3033945237 hasConceptScore W3033945237C126322002 @default.
• W3033945237 hasConceptScore W3033945237C143998085 @default.
• W3033945237 hasConceptScore W3033945237C2776256026 @default.
• W3033945237 hasConceptScore W3033945237C2776283816 @default.
• W3033945237 hasConceptScore W3033945237C2776694085 @default.
• W3033945237 hasConceptScore W3033945237C2777014857 @default.
• W3033945237 hasConceptScore W3033945237C2777543607 @default.
• W3033945237 hasConceptScore W3033945237C2777714996 @default.
• W3033945237 hasConceptScore W3033945237C2778341716 @default.
• W3033945237 hasConceptScore W3033945237C2781244666 @default.
• W3033945237 hasConceptScore W3033945237C61511704 @default.
• W3033945237 hasConceptScore W3033945237C71924100 @default.
• W3033945237 hasConceptScore W3033945237C90924648 @default.
• W3033945237 hasIssue "3" @default.
• W3033945237 hasLocation W30339452371 @default.
• W3033945237 hasLocation W30339452372 @default.
• W3033945237 hasLocation W30339452373 @default.
• W3033945237 hasLocation W30339452374 @default.
• W3033945237 hasOpenAccess W3033945237 @default.
• W3033945237 hasPrimaryLocation W30339452371 @default.
• W3033945237 hasRelatedWork W2158124765 @default.
• W3033945237 hasRelatedWork W2794339623 @default.
• W3033945237 hasRelatedWork W2908163910 @default.
• W3033945237 hasRelatedWork W3013007024 @default.
• W3033945237 hasRelatedWork W3020796533 @default.
• W3033945237 hasRelatedWork W3032193866 @default.
• W3033945237 hasRelatedWork W3142039466 @default.
• W3033945237 hasRelatedWork W4210603043 @default.

• next